{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:20Z","timestamp":1793320640049,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Because anaplastic thyroid cancer (ATC) is a rare diagnosis, detailed epidemiological data are difficult to find in publicly accessible platforms. The aim of this study was to report current incidence and survival estimates for ATC in Germany and to analyse their trends over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the population-based cancer registries in Germany were pooled. ATC was classified according to the International Classification of Diseases, 10th edition (ICD-10). Age-standardised incidence rates (per 100,000) for the years 2011 to 2022 were calculated. The relative survival was estimated using period analysis. Annual percentage changes (APC) in the incidence and survival trends over time were computed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      The number of new ATC cases diagnosed between 2011 and 2022 was 2127 (924 in men and 1203 in women). The current raw incidence is 0.19 in men and 0.22 in women. The age-standardised incidence in men changed slightly, but not significantly, during this period (APC\u2009\u2212\u20092%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.126; recent rate 0.11) while it decreased in women (APC\u2009\u2212\u20093%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; recent rate 0.10). The five-year relative survival ranged from 11% (2020\u20132022) to 15% (2017\u20132019) and decreased considerably with age. There were no differences in survival between men and women and no evidence for a change in survival over time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>About two persons per 1\u00a0million inhabitants are currently diagnosed with ATC per year. Over the past 12 years, there was a slight decrease in ATC incidence, especially in women, while survival remained largely unchanged during this period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04643-2","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:38:39Z","timestamp":1777876719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anaplastic thyroid cancer: Cases, incidence, prevalence and survival in Germany"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-7964","authenticated-orcid":false,"given":"Susanne","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0768-5789","authenticated-orcid":false,"given":"Katherine J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9441-3046","authenticated-orcid":false,"given":"Yara Maria","family":"Machlah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-4341","authenticated-orcid":false,"given":"Tim","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-1950","authenticated-orcid":false,"given":"Kerstin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3241-0728","authenticated-orcid":false,"given":"Sabine","family":"W\u00e4chter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-6003","authenticated-orcid":false,"given":"Klaus","family":"Kraywinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4638-3679","authenticated-orcid":false,"given":"Markus","family":"Luster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-6817","authenticated-orcid":false,"given":"Friederike","family":"Eilsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"9","key":"4643_CR1","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"B. Lin, H.Q. Ma, M.G. Ma et al., The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am. J. Transl Res. 11(9), 5888\u20135896 (2019)","journal-title":"Am. J. Transl Res."},{"issue":"10","key":"4643_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm9103231","volume":"9","author":"T Augustin","year":"2020","unstructured":"T. Augustin, D. Oliinyk, V.F. Koehler et al., Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients. J. Clin. Med. 9(10), 21 (2020). https:\/\/doi.org\/10.3390\/jcm9103231","journal-title":"J. Clin. Med."},{"issue":"1","key":"4643_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beem.2022.101678","volume":"37","author":"SN Rao","year":"2023","unstructured":"S.N. Rao, R.C. Smallridge, Anaplastic thyroid cancer: An update. Best Pract. Res. Clin. Endocrinol. Metab. 37(1), 13 (2023). https:\/\/doi.org\/10.1016\/j.beem.2022.101678","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"3","key":"4643_CR4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00405-023-07827-y","volume":"280","author":"E Maurer","year":"2023","unstructured":"E. Maurer, F. Eilsberger, S. Waechter et al., Mutation-based, short-term neoadjuvant treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur. Arch. Oto-Rhino-Laryn. 280(3), 1509\u20131518 (2023). https:\/\/doi.org\/10.1007\/s00405-023-07827-y","journal-title":"Eur. Arch. Oto-Rhino-Laryn"},{"issue":"1","key":"4643_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/21645515.2024.2403170","volume":"20","author":"QY Wang","year":"2024","unstructured":"Q.Y. Wang, G. Pan, Y. Zhang, Y.Q. Ni, Y.Z. Mu, D.C. Luo, Emerging insights into thyroid cancer from immunotherapy perspective: A bibliometric analysis. Hum. Vaccines Immunother. 20(1), 15 (2024). https:\/\/doi.org\/10.1080\/21645515.2024.2403170","journal-title":"Hum. Vaccines Immunother"},{"issue":"4","key":"4643_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"V. Subbiah, R.J. Kreitman, Z.A. Wainberg et al., Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann. Oncol. 33(4), 406\u2013415 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014","journal-title":"Ann. Oncol."},{"issue":"7","key":"4643_CR7","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"C. Dierks, J. Seufert, K. Aumann et al., Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid. 31(7), 1076\u20131085 (2021). https:\/\/doi.org\/10.1089\/thy.2020.0322","journal-title":"Thyroid"},{"key":"4643_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fendo.2021.712107","volume":"12","author":"P Adam","year":"2021","unstructured":"P. Adam, S. Kircher, I. Sbiera et al., FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. Front. Endocrinol. 12, 12 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.712107","journal-title":"Front. Endocrinol."},{"issue":"3","key":"4643_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"K.C. Bible, E. Kebebew, J. Brierley et al., 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 31(3), 337\u2013386 (2021). https:\/\/doi.org\/10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"issue":"12","key":"4643_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"S. Filetti, C. Durante, D. Hartl et al., Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(12), 1856\u20131883 (2019). https:\/\/doi.org\/10.1093\/annonc\/mdz400","journal-title":"Ann. Oncol."},{"key":"4643_CR11","volume-title":"S3-Leitlinie Schilddr\u00fcsenkarzinom, Langversion 1.0","author":"A Bockisch","year":"2025","unstructured":"A. Bockisch, S3-Leitlinie Schilddr\u00fcsenkarzinom, Langversion 1.0 (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF, Berlin, 2025)"},{"issue":"4","key":"4643_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/s2213-8587(21)00027-9","volume":"9","author":"A Miranda-Filho","year":"2021","unstructured":"A. Miranda-Filho, J. Lortet-Tieulent, F. Bray et al., Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4), 225\u2013234 (2021). https:\/\/doi.org\/10.1016\/s2213-8587(21)00027-9","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4643_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fendo.2025.1585679","volume":"16","author":"HP Guo","year":"2025","unstructured":"H.P. Guo, J.J. Zhang, Y.J. Jia et al., Trends in incidence, mortality, and conditional survival of anaplastic thyroid cancer over the last two decades in the USA. Front. Endocrinol. 16, 11 (2025). https:\/\/doi.org\/10.3389\/fendo.2025.1585679","journal-title":"Front. Endocrinol."},{"issue":"3","key":"4643_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejca.2003.10.013","volume":"40","author":"H Brenner","year":"2004","unstructured":"H. Brenner, O. Gefeller, T. Hakulinen, Period analysis for \u2018up-to-date\u2019 cancer survival data: theory, empirical evaluation computational realisation and applications. Eur. J. Cancer. 40(3), 326\u2013335 (2004). https:\/\/doi.org\/10.1016\/j.ejca.2003.10.013","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"4643_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/jco.20.3.826","volume":"20","author":"H Brenner","year":"2002","unstructured":"H. Brenner, T. Hakulinen, Up-to-date long-term survival curves of patients with cancer by period analysis. J. Clin. Oncol. 20(3), 826\u2013832 (2002). https:\/\/doi.org\/10.1200\/jco.20.3.826","journal-title":"J. Clin. Oncol."},{"key":"4643_CR16","volume-title":"Instructions to IBM 650 programmers in processing survival computations","author":"F Ederer","year":"1959","unstructured":"F. Ederer, H. Heise, Instructions to IBM 650 programmers in processing survival computations (National Cancer Institute, Bethesda, MD, 1959)"},{"issue":"1","key":"4643_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ijc.1571","volume":"97","author":"P Pisani","year":"2002","unstructured":"P. Pisani, F. Bray, D.M. Parkin, Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer. 97(1), 72\u201381 (2002). https:\/\/doi.org\/10.1002\/ijc.1571","journal-title":"Int. J. Cancer"},{"issue":"2","key":"4643_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/thy.2010.0021","volume":"21","author":"B Aschebrook-Kilfoy","year":"2011","unstructured":"B. Aschebrook-Kilfoy, M.H. Ward, M.M. Sabra, S.S. Devesa, Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992\u20132006. Thyroid. 21(2), 125\u2013134 (2011). https:\/\/doi.org\/10.1089\/thy.2010.0021","journal-title":"Thyroid"},{"issue":"2","key":"4643_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1530\/ERC-12-0336","volume":"20","author":"O Husson","year":"2013","unstructured":"O. Husson, H.R. Haak, van L.N. Steenbergen et al., Rising incidence, no change in survival and decreasing mortality from thyroid cancer in The Netherlands since 1989. Endocr. Relat. Cancer. 20(2), 263\u2013271 (2013)","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"4643_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje-20-0080","volume":"183","author":"M de Ridder","year":"2020","unstructured":"de M. Ridder, van E.N. Dijkum, A. Engelsman, E. Kapiteijn, H.J. Kl\u00fcmpen, C.R.N. Rasch, Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur. J. Endocrinol. 183(2), 203\u2013209 (2020). https:\/\/doi.org\/10.1530\/eje-20-0080","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"4643_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3803\/EnM.2020.807","volume":"35","author":"YH Bai","year":"2020","unstructured":"Y.H. Bai, K. Kakudo, C.K. Jung, Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification. Endocrinol. Metab. 35(4), 696\u2013715 (2020). https:\/\/doi.org\/10.3803\/EnM.2020.807","journal-title":"Endocrinol. Metab."},{"issue":"15","key":"4643_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.2010.28.15_suppl.5588","volume":"28","author":"AM Hossain","year":"2010","unstructured":"A.M. Hossain, R.N. Rahman, G. Nagaiah, R. Altaha, S.C. Remick, Epidemiology, treatment outcome, and survival of anaplastic thyroid cancer (ATC) in the United States: A period prevalence SEER database study 1973\u20132006. J. Clin. Oncol. 28(15), 1 (2010). https:\/\/doi.org\/10.1200\/jco.2010.28.15_suppl.5588","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"4643_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1089\/thy.2015.0116","volume":"25","author":"S Vaccarella","year":"2015","unstructured":"S. Vaccarella, L. Dal Maso, M. Laversanne, F. Bray, M. Plummer, S. Franceschi, The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries. Thyroid. 25(10), 1127\u20131136 (2015). https:\/\/doi.org\/10.1089\/thy.2015.0116","journal-title":"Thyroid"},{"issue":"3","key":"4643_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-2006-926641","volume":"68","author":"S Scheffer","year":"2006","unstructured":"S. Scheffer, S. Dauven, M. Sieverding, Sociodemograhic differences in the participation in early detection of cancer examinations in Germany - a review. Gesundheitswesen. 68(3), 139\u2013146 (2006). https:\/\/doi.org\/10.1055\/s-2006-926641","journal-title":"Gesundheitswesen"},{"issue":"4","key":"4643_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3238\/arztebl.m2024.0005","volume":"121","author":"S Singer","year":"2024","unstructured":"S. Singer, A. W\u00fcnsch, A. Ihrig et al., Men\u2019s access to outpatient psychosocial cancer counselling - a cluster-randomized trial. Dtsch. Arztebl Int. 121(4), 121\u2013127 (2024). https:\/\/doi.org\/10.3238\/arztebl.m2024.0005","journal-title":"Dtsch. Arztebl Int."},{"issue":"3","key":"4643_CR26","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1055\/a-0820-3584","volume":"82","author":"J Keil","year":"2020","unstructured":"J. Keil, V. Brendler, C. Sachse et al., Gender-Specific Differences in the Utilization of Health Care Services in an Urban Population Sample. Gesundheitswesen. 82(3), E17\u2013E23 (2020). https:\/\/doi.org\/10.1055\/a-0820-3584","journal-title":"Gesundheitswesen"},{"issue":"2","key":"4643_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.eprac.2025.08.007","volume":"32","author":"L Croce","year":"2026","unstructured":"L. Croce, R.M. Ruggeri, M. Teliti et al., Redefining Thyroid Nodule Evaluation: Demographics, Misleading Symptoms, and Diagnostic Challenges. Insights From a Multicenter Study. Endocr. Pract. 32(2), 142\u2013148 (2026). https:\/\/doi.org\/10.1016\/j.eprac.2025.08.007","journal-title":"Endocr. Pract."},{"key":"4643_CR28","doi-asserted-by":"publisher","unstructured":"I. Cosme, A. Figueiredo, S. Pinheiro, V. Leite, Incidentally vs non-incidentally diagnosed papillary thyroid carcinoma: are there differences? Eur. Thyroid J. 13(4) (2024). https:\/\/doi.org\/10.1530\/etj-24-0106","DOI":"10.1530\/etj-24-0106"},{"issue":"7","key":"4643_CR29","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.oraloncology.2013.03.440","volume":"49","author":"JP O\u2019Neill","year":"2013","unstructured":"J.P. O\u2019Neill, A.R. Shaha, Anaplastic thyroid cancer. Oral Oncol. 49(7), 702\u2013706 (2013). https:\/\/doi.org\/10.1016\/j.oraloncology.2013.03.440","journal-title":"Oral Oncol."},{"issue":"2","key":"4643_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2265.2004.02187.x","volume":"62","author":"RM Reynolds","year":"2005","unstructured":"R.M. Reynolds, J. Weir, D.L. Stockton, D.H. Brewster, T.C. Sandeep, M.W.J. Strachan, Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin. Endocrinol. 62(2), 156\u2013162 (2005). https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02187.x","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"4643_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ecl.2025.03.009","volume":"54","author":"S Hamidi","year":"2025","unstructured":"S. Hamidi, A. Maniakas, M.E. Cabanillas, Advances in Anaplastic Thyroid Cancer Treatment. Endocrinol. Metab. Clin. North Am. 54(3), 361\u2013375 (2025). https:\/\/doi.org\/10.1016\/j.ecl.2025.03.009","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"9","key":"4643_CR32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"A. Maniakas, R. Dadu, N.L. Busaidy et al., Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000\u20132019. JAMA Oncol. 6(9), 1397\u20131404 (2020). https:\/\/doi.org\/10.1001\/jamaoncol.2020.3362","journal-title":"JAMA Oncol."},{"key":"4643_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00432-025-06403-7","volume":"152","author":"T Augustin","year":"2026","unstructured":"T. Augustin, D. Oliinyk, M. Haderlein et al., Impact of comorbidities on treatment management and prognosis in patients with anaplastic thyroid cancer (ATC). J. Cancer Res. Clin. Oncol. 152, 22 (2026). https:\/\/doi.org\/10.1007\/s00432-025-06403-7","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"8","key":"4643_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/bjs\/znae199","volume":"111","author":"M Raffaelli","year":"2024","unstructured":"M. Raffaelli, N. Voloudakis, M. Barczynski et al., European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management. Br. J. Surg. 111(8), 24 (2024). https:\/\/doi.org\/10.1093\/bjs\/znae199","journal-title":"Br. J. Surg."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04643-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:59:19Z","timestamp":1781650759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04643-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4643"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04643-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study required no ethics approval as the use of the cancer registry data is enabled by law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"174"}}